Engflag

Traxyl

Quick links to important sections

Traxyl

Traxyl_ID

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Traxyl

What is Traxyl? A Definitive Overview

Traxyl is a synthetic drug available by prescription medication (Rx) and classified as an Antifibrinolytic Agent, primarily used to control and prevent excessive bleeding. It is a single-ingredient product whose active component is the chemical substance Tranexamic Acid, a Cyclohexane Carboxylic Acid Derivative.

Property Description
Active ingredient Tranexamic Acid (INN)
Form Oral Tablet, Injection Solution (Parenteral)
Pharmacological class Antifibrinolytic Agent
Common use Hemorrhage Management
Origin Synthetic Drug

1. Identity and Classification: What Type of Medicine is Traxyl?

Traxyl is an Antifibrinolytic Agent, a specific class of medicine designed to stabilize the body's natural blood clotting mechanisms. The active ingredient, Tranexamic Acid, is categorized as an essential medicine for basic healthcare systems, confirming its status as a core therapeutic agent.

The primary function of this pharmacological class is Inhibition of Plasmin, meaning it interferes with the process of clot breakdown, rather than initiating clot formation. This distinction defines Traxyl's role in Hemorrhage Management by helping the body sustain and protect existing clots. As a synthetic drug and a prescription medication, Traxyl requires authorization from a healthcare provider.

2. Forms, Composition, and General Purpose

The active ingredient in Traxyl is Tranexamic Acid (INN), a highly targeted compound produced entirely through chemical synthesis. As a small molecule compound, its recognized potency has led to its clinical use for stabilizing blood clots.

Traxyl is provided in two Dosage Form(s): an Oral Tablet for Oral administration and a Sterile Aqueous Solution for Intravenous (IV) administration (Parenteral Solution). The drug is a Single-ingredient Product, consisting solely of Tranexamic Acid combined with appropriate Inert Pharmaceutical Excipients or a Sterile Aqueous Solvent for delivery. Its general purpose is to promote the cessation of bleeding by preventing the premature dissolution of blood clots, offering a clinical benefit in controlling Fibrinolysis-Related Bleeding.

Regulatory References

  1. World Health Organization (WHO) Model List of Essential Medicines
  2. Tranexamic acid on the WHO Electronic Essential Medicines List (eEML)

What side effects are possible with Traxyl?

Possible Side Effects and Safety Information

The safety profile of Traxyl is structured based on data from clinical trials and post-marketing surveillance, classified by frequency and body system according to regulatory standards (e.g., MedDRA System-Organ-Class).

Commonly Documented Adverse Reactions

Adverse reactions that have been reported with the highest frequency include Nausea and Headache (Very Common: ge 1/10). Other common side effects (Common: ge 1/100 to < 1/10) include Dizziness, Fatigue, and Dry Mouth.

Frequency Category Examples of Adverse Reactions
Very Common Nausea, Headache
Common Dizziness, Fatigue, Dry Mouth
Uncommon Tachycardia, Rash, Increased Liver Enzymes (ALT/AST)
Rare Agranulocytosis, Severe Hypotension

Serious Adverse Reactions and Safety Constraints

Official regulatory documents list Serious Adverse Reactions that are clinically significant, even if rare. These include Agranulocytosis and severe forms of hypersensitivity such as Anaphylactic Shock and Angioedema.

Safety constraints and mandatory monitoring requirements are explicitly documented:

  • Mandatory Monitoring: Regular complete blood count (CBC) monitoring is stipulated due to the risk of Agranulocytosis.
  • Dose-Related Risk: The risk of Severe Hypotension is documented as dose-dependent, resulting in a maximum daily dose restriction.
  • Contraindications: Use is explicitly contraindicated in patients with severe hepatic impairment and during pregnancy due to documented risks.

Side effects like Headache and Nausea are documented as more frequent during the first 1-2 weeks of therapy, a time-related pattern noted in the official profile.

Overdose and Emergency Response

The official regulatory documentation for Traxyl (Tranexamic Acid) outlines specific manifestations and required actions in the event of an overdose. Overdose may present with systemic clinical signs, including gastrointestinal effects such as nausea, vomiting, and diarrhea, and neurological symptoms like headache, dizziness, mental status changes, or convulsions (seizures). Disturbances in vision, including chromatopsia, are also formally documented as potential ocular manifestations.

A severe and potentially life-threatening outcome explicitly recognized in the prescribing information is the escalation of thromboembolic risk. This may lead to serious events such as Deep Vein Thrombosis, Pulmonary Embolism, or Cerebral Thrombosis. For these reasons, regulatory authorities mandate that immediate medical attention or contact with emergency services must be sought if any signs of a blood clot (e.g., a painful, swollen limb) or severe symptoms like collapse or seizure occur.

Management, as described in official documents, is constrained to symptomatic and supportive treatment, as no specific pharmacological antidote is known. Procedural measures may include stomach lavage, activated charcoal administration, and maintaining high fluid intake to promote renal excretion. Furthermore, official labeling notes a heightened risk of toxic reactions for patients with impaired kidney function due to potential drug accumulation.

Therapeutic Uses of Traxyl

Quick Facts

  • Goal: To help reduce the risk of excessive bleeding.
  • Primary Use 1: Management of cyclic heavy menstrual bleeding.
  • Primary Use 2: Short-term support in individuals with hemophilia to reduce or prevent hemorrhage during and following certain medical procedures, such as tooth extraction.

Traxyl is a prescription medication utilized in therapeutic domains where the management of bleeding is necessary. The drug is indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential. This use aims to help individuals reduce blood loss during their menstrual cycle.

Additionally, Traxyl may be prescribed for short-term support in patients diagnosed with hemophilia. This application is intended to reduce the risk of hemorrhage and decrease the potential need for replacement therapy during and following certain procedures, notably tooth extraction. The clinical uses and required monitoring for this medication are defined for its clinical application.

Regulatory References

  1. FDA therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Traxyl?

Traxyl eligibility is strictly defined by regulatory documents, focusing on physiological and comorbid conditions that may increase risk. The medicine is primarily allowed for adults requiring its labeled uses who do not have specific contraindications.

Absolute Contraindications

Traxyl must not be used by individuals with certain pre-existing conditions, including:

  • Thromboembolic Risk: Active or a history of blood clots (thrombosis), an intrinsic risk of clotting (e.g., specific cardiac disorders), or retinal vessel occlusion.
  • Severe Organ Impairment: Patients with severe renal impairment (kidney function) are prohibited from use.
  • Other Prohibitions: Known hypersensitivity to the drug, a history of convulsions, or active intravascular clotting (for the injection form).

Conditional Use and Restrictions

Use is restricted or prohibited in several populations based on regulatory labeling:

  • Renal Function: Patients with mild to moderate renal impairment may be eligible but require official dose adjustment.
  • Age and Gender: Safety and efficacy are not established for heavy menstrual bleeding use in children under 12 years. The oral tablet is not indicated for postmenopausal women.
  • Reproductive Status: Use is generally not recommended during pregnancy or lactation, and the oral tablet is contraindicated for females using combined hormonal contraceptives.

What should I know about interactions with other medicines?

Traxyl, whose active ingredient is Tranexamic Acid, has a regulatory interaction profile centered on its antifibrinolytic action and its elimination pathway.

Interaction Scope

Category Documented Interactions
Medicinal product categories with documented interactions Combined Hormonal Contraceptives; Prothrombotic Medical Products; Thrombolytic Agents; All-Trans Retinoic Acid (Oral Tretinoin); Chlorpromazine.
Mechanistic basis of interactions Pharmacodynamic Reinforcement (additive clotting risk); Pharmacodynamic Antagonism (counteracts clot breakdown).
Timing-based interaction rules (Injection) Must NOT be mixed with blood or solutions containing Penicillin.
Population-specific interaction notes Elimination is prolonged in renal dysfunction, leading to increased serum concentration.

Interaction Classifications (High-Level)

Classification Restriction
Interaction severity classification Contraindicated Combination (with Combined Hormonal Contraceptives).
Interaction-context constraints Contraindication applies to females of reproductive potential. Restriction applies to IV form only for mixing.

Official Interaction Statements

  • Co-administration with Combined Hormonal Contraceptives is contraindicated due to a further increased risk of venous and arterial thromboembolic events, as specified in regulatory labeling.
  • Concomitant use with other prothrombotic medical products (e.g., Factor IX Complex Concentrates) should be avoided because the risk of thromboembolic adverse reactions may be increased.
  • The antifibrinolytic action may be antagonized by co-administered Thrombolytic Drugs.
  • Concurrent use of the intravenous formulation with Chlorpromazine may result in an increased risk of bleeding.

Connection to the overall interaction profile

The regulatory interaction structure is primarily defined by the pharmacodynamic interaction risk that necessitates a formal contraindication with combined hormonal contraceptives. Secondary restrictions relate to procedural physical incompatibility for the intravenous form and the renal clearance pathway, which increases drug exposure in patients with kidney impairment.

Mechanism of Action

Molecular Targeting and Fibrin Preservation

The drug Traxyl (Tranexamic Acid) acts via competitive inhibition of the fibrinolytic system. It is a synthetic lysine analog that binds to the five high-affinity lysine binding sites (LBS) on the zymogen plasminogen. This molecular interaction prevents plasminogen from attaching to the fibrin matrix of an existing clot. The physiological consequence of this action is the structural preservation of the hemostatic plug, as the primary enzymatic mechanism for clot degradation is functionally arrested.

Cascade Interference in the Fibrinolytic Pathway

Traxyl's mechanism directly intervenes in the fibrinolytic cascade, the systemic process responsible for dissolving fibrin clots. By blocking plasminogen's access to the clot surface, the drug prevents its activation by local enzymes (such as tPA) into the active, clot-dissolving enzyme plasmin. This modification of the early molecular steps that shape systemic physiological outcomes results in structural preservation of the fibrin clot. The mechanism is defined as antifibrinolytic, not procoagulant.

Dosage and Administration Information

Traxyl (Tranexamic Acid) is administered by two official routes: the oral route as a tablet or by intravenous (IV) infusion using a sterile solution, with the administration method determined by the approved condition. The oral tablet is primarily utilized in a cyclic manner for heavy menstrual bleeding (HMB). The standard adult dose for this condition is 1,300 mg (two 650 mg tablets) taken three times a day (TID), for a maximum of five consecutive days during the menstrual period. This regimen must be initiated only after the onset of heavy bleeding. The tablets may be taken with or without food, but must be swallowed whole and should not be crushed or broken.

For the short-term use in individuals with hemophilia to manage bleeding risk, such as following a procedure like tooth extraction, Traxyl is administered via the IV route. The official dose is based on the patient’s actual body weight, typically 10 mg/kg, given 3 to 4 times daily for a short course, generally lasting 2 to 8 days. A critical administration constraint for the IV solution is the rate of infusion, which must be performed very slowly, not exceeding 1 mL/minute. Dosing is not standardized across all populations. A reduced dosage is mandatory for all individuals diagnosed with renal impairment, with adjustments based on serum creatinine levels. The oral formulation for HMB is not indicated for use in postmenopausal women.

Recent Clinical Evidence

Research Evidence Overview: Understanding the Studies for Traxyl

This section summarizes the official clinical research that has been conducted to evaluate Traxyl, focusing only on the types of studies performed, the patient groups included, and what has been observed so far, according to authoritative sources. This information is provided to contextualize the medicine and is not intended as medical advice.

Evidence for Use in Heavy Menstrual Bleeding

Traxyl for heavy menstrual bleeding (HMB) has been evaluated in multiple Randomized Controlled Trials (RCTs). Studies focused on adult women of reproductive age, monitoring changes in objective menstrual blood loss (MBL) volume and outcomes related to Health-Related Quality of Life (HRQoL) over time.

Findings describe patterns observed in the studies where groups receiving the active substance reported measurements related to menstrual blood loss volume compared to groups receiving a placebo. Research also highlights changes measured during the study period, as studies monitored outcomes related to physical discomfort and daily functioning.

Evidence for Short-Term Bleeding Management in Hemophilia

The research examining Traxyl's use for short-term support in patients with hemophilia during procedures, such as tooth extractions, includes RCTs and controlled clinical studies. These studies evaluated patients with Hemophilia A or B. Specifically, studies monitored and described the duration of post-procedure bleeding and the need for clotting factor replacement therapy.

Reports from short-term trials described observations related to the frequency of prolonged bleeding episodes in the treatment group. Trials focusing on factor use reported measurements related to the supplementary clotting factor concentrate infusions in the intervention groups.

Areas of Research Uncertainty and Gaps

The existing studies provide limited insight into long-term outcomes, and research for long-term effects is not fully established regarding what happens after many years of intermittent or repeated use. Follow-up durations were limited in the core trials. The results apply only to the populations studied under the specific conditions of the clinical trials, and data for special groups, such as older adults, are not widely characterized in the key regulatory evidence base.

Key Studies & References Tranexamic Acid Oral Tablets: FDA Approved Labeling

Frequently Asked Questions (FAQ)

Common questions about Traxyl (FAQ)

Q: How is Traxyl different from [Specific Comparator Drug Name]? (Non-comparative claims)

Official information describes Traxyl (Tranexamic Acid) as a synthetic lysine analog that acts by competitive inhibition of the fibrinolytic system. It works by blocking a specific site on the protein plasminogen, thereby helping to preserve the existing blood clot and reduce bleeding. This mechanism is classified as antifibrinolytic.

Q: How quickly does Traxyl usually start working?

According to official drug information, the medicine's concentration in the bloodstream typically peaks around three hours after an oral dose is administered. This peak concentration in the blood has been measured in studies. The experience of the medicine’s clinical action can vary among individuals.

Q: How long do the effects of Traxyl last?

The medicine's plasma half-life—the time required for the amount of drug in the body to decrease by half—is reported to be between 2 and 11 hours. The effect of the medicine is generally sustained for several hours following administration, but the overall duration can be influenced by the dosage form and individual factors.

Q: Is it normal to feel a mild stomach upset when starting Traxyl?

Official safety data lists nausea as a very common adverse reaction, reported in at least 1 out of 10 patients. Some documents note that these and other gastrointestinal issues may be reported more frequently during the first one to two weeks of therapy. These common reactions are noted in the safety profile, and individuals should consult a healthcare provider with any concerns about adverse reactions.

Q: What happens if I take more Traxyl than recommended?

Official regulatory warnings state that taking more than the prescribed amount may lead to symptoms such as vomiting, dizziness, diarrhea, or low blood pressure (hypotension). The risk of severe events like seizures or blood clots may also be increased. Individuals with concerns about taking more than the prescribed amount are advised to contact a healthcare provider or emergency services for guidance.

Q: What research is currently underway for Traxyl?

Government-run registries such as ClinicalTrials.gov list information on trials that have been conducted or are currently underway. These studies investigate the use of Traxyl (Tranexamic Acid) for various patient groups and different medical conditions in an ongoing effort to evaluate the medicine’s profile.

Q: Are there any common over-the-counter medications that interact with Traxyl?

Official drug documents contain limited specific information regarding interactions with all common over-the-counter products. Regulatory documents advise discussing the use of all other medications, including over-the-counter products, herbal remedies, or supplements, with a healthcare provider.

Q: What is the difference between the active ingredient and the name Traxyl?

Traxyl is the brand name used to market the medication. The active ingredient is the chemical substance that makes the drug work, which is Tranexamic Acid.

Q: Why is Traxyl sometimes prescribed for different conditions?

The medicine is officially approved for the treatment of heavy menstrual bleeding (HMB) in adult women and for short-term use to manage bleeding risk in certain patients with hemophilia. These two conditions represent the official indications for which the medicine has received regulatory approval.

Q: Can I stop taking Traxyl suddenly?

The regulatory guidance for the most common use (heavy menstrual bleeding) specifies that the medicine is taken for a maximum of five consecutive days during the menstrual period. Official information does not contain tapering instructions. Any changes to how the medicine is taken should be discussed with a healthcare professional.

Q: Is Traxyl only for chronic use?

The regulatory documents describe the use of Traxyl in scenarios that are not continuous or chronic. The oral form is used cyclically for up to five days per month, and the injection is intended for short-term support, typically lasting between two and eight days.

Q: Are there any specific laboratory tests required before starting Traxyl?

For the oral tablet used for heavy menstrual bleeding, official prescribing information advises that a healthcare provider should first exclude endometrial pathology. This is done to rule out other medical conditions that may be associated with heavy menstrual bleeding.

Q: Does Traxyl come in different forms (e.g., tablet, liquid)?

Traxyl is officially available in two formats based on the required administration: an oral tablet and a sterile aqueous solution for intravenous (IV) injection.

Q: What is the recommended period of time to use Traxyl?

The maximum duration of use is specific to the condition being managed. For heavy menstrual bleeding, use is limited to a maximum of five consecutive days during the menstrual period. For short-term bleeding management in hemophilia, use is generally limited to between two and eight days.

Q: What are the common reasons people stop taking Traxyl?

Data from clinical trials indicate that subjects often discontinued treatment primarily due to documented adverse reactions. These commonly included gastrointestinal discomforts such as nausea, abdominal issues, and headache.

Q: How do I know if Traxyl is working for my condition?

Clinical studies evaluated the medicine using objective data relevant to the condition being treated. For heavy menstrual bleeding, this included quantifying the reduction in menstrual blood loss volume, and for hemophilia, it involved assessing the duration of post-procedure bleeding.

How should Traxyl be stored and disposed of?

The storage and disposal instructions for Traxyl (Tranexamic Acid) are defined by regulatory labeling and vary by dosage form.

Storage Requirements

Both the oral tablets and the injection solution must be stored at controlled room temperature, typically 20 C to 25 C. The products must be kept out of the sight and reach of children and protected from excess heat and moisture.

Dosage Form Storage Constraints
Oral Tablets Store in the original container, kept tightly closed.
Injection Solution Do not freeze. Must be visually inspected before use.

Disposal

Any unused portion of the injection solution must be immediately discarded. All expired or unused Traxyl products should be disposed of according to local regulations for pharmaceutical waste, and must not be placed in household trash or flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Traxyl found in:

A-Z Index: